Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vesanoid (tretinoin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

Cytotoxic T lymphocyte stimulant, Telomerase inhibitor, Retinoic acid receptor agonist

Related drugs:

‹

›

MYB underexpression	Adenoid Cystic Carcinoma	MYB underexpression	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
NOTCH1 mutation	Adenoid Cystic Carcinoma	NOTCH1 mutation	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3